CHD4 and breast cancer: Low CHD4 expression may promote either resistance or sensitivity to therapeutic agents [cisplatin, poly-ADP-ribose polymerase (ARP) inhibitor, or trastuzumab] via different molecular pathways according to the type of BC in question.